{"id":"W4281650201","doi":"10.1200/jco.2022.40.16_suppl.tps8072","title":"MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Lenalidomide; Medicine; Pomalidomide; Internal medicine; Oncology; Multiple myeloma; Bortezomib; Dexamethasone; Progressive disease; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003379003,0.001980846,0.002639524,0.0005038353,0.0006574641,0.001657884,0.001522632,0.002539723,0.00815033],"category_scores_gemma":[0.002281296,0.0009549078,0.00279538,0.0005291573,0.001548516,0.001798795,0.0005967404,0.006352079,0.001742523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001640246,"about_ca_system_score_gemma":0.002257388,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001959188,"about_ca_topic_score_gemma":0.005786964,"domain_scores_codex":[0.9992141,0.0004109596,0.00003499865,0.0001432477,0.00006713793,0.0001295034],"domain_scores_gemma":[0.9985899,0.0003433499,0.0003079468,0.00009957662,0.00009307205,0.0005660192],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.973371,0.0104483,0.0006432991,0.0003691131,0.0008150198,0.00006044109,0.00006439776,0.0004657679,0.001994021,0.0001393191,0.001960898,0.009668401],"study_design_scores_gemma":[0.9458386,0.05109835,0.001160691,0.00002018713,0.0002088613,0.000049595,0.00001811063,0.0004642228,0.0001798676,0.0001968953,0.0007509441,0.00001383049],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9697122,0.005996864,0.001168326,0.002281935,0.001262095,0.01132045,0.003667175,0.0003891301,0.004201804],"genre_scores_gemma":[0.968031,0.003119127,0.003333536,0.004387178,0.0008007826,0.01087921,0.004031685,0.00009980367,0.005317842],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00815033,"threshold_uncertainty_score":0.02726561,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1191458296945169,"score_gpt":0.4442931853155352,"score_spread":0.3251473556210183,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}